# EV-104 (NCT05014139)

> A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC)

No report yet. It can be ordered.

- Drugs tested: intravesical enfortumab vedotin
- Indication: non-muscle invasive bladder cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05014139
- Phase: PHASE1
- Status: TERMINATED
- Sponsor: Astellas Pharma Global Development, Inc.
- Conditions: Urinary Bladder Neoplasms; Carcinoma in Situ; Carcinoma Transitional Cell; Non-muscle Invasive Bladder Cancer; NMIBC
- Interventions: Enfortumab vedotin
- Enrollment: 37
- Primary outcome: Incidence of adverse events (AEs)
- Primary outcome: Incidence of laboratory abnormalities
- Primary outcome: Incidence of dose limiting toxicities (DLTs)

## Indexed commentary on EV-104 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 6
- YouTube: 4
- Podcasts: 2

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=ev-104-nct05014139

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05014139", "email": "<work email>"}; the inbox owner confirms by the emailed link.